Deeba Amraiz,
Najam-us-Sahar Sadaf Zaidi 
,
Munazza Fatima
For correspondence:- Najam-us-Sahar Zaidi Email: zaidi.sahar@gmail.com Tel:+925190856132
Received: 17 November 2016 Accepted: 7 April 2017 Published: 30 May 2017
Citation: Amraiz D, Zaidi NS, Fatima M. Antiviral evaluation of an Hsp90 inhibitor, gedunin, against dengue virus. Trop J Pharm Res 2017; 16(5):997-1004 doi: 10.4314/tjpr.v16i5.5
© 2017 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To evaluate the antiviral potential of a tetranortriterpenoid, gedunin, against dengue virus (DENV) replication by targeting the host chaperone, Hsp90.
Methods: The compound, gedunin, was tested against the replication of DENV in vitro using BHK-15 cells transfected with DENV-2 subgenomic replicon. Molecular docking of gedunin with Hsp90 protein was performed for evaluation of mode of action, using the program, Autodock vina.
Results: In vitro antiviral data showed that gedunin significantly (p < 0.05) reduced DENV replication with EC50 of 10 µM. Further, in silico molecular docking data revealed strong interaction of gedunin with the ATP/ADP binding site of the host protein, Hsp90, with an estimated average free binding energy of -8.9 kcal/mol.
Conclusion: The results validate gedunin as a potential antiviral candidate. Further in vitro assays and in vivo viral challenge studies are required to confirm the exact mode of action and pharmacological profile of gedunin in DENV infections
Fulltext in PDF